Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis

The past decade has witnessed a transformation in the treatment of rifampicin-resistant/multidrug-resistant (RR/MDR) tuberculosis (TB), with a four-drug, 6-month regimen supported by high-quality evidence now being recommended for most adults. Children (

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2023-07, Vol.208 (2), p.130-131
Main Authors: Patankar, Sayalee, Cruz, Andrea T, Douglas-Jones, Bianca, Garcia-Prats, Anthony, Kay, Alexander, Reuter, Anja, Schaaf, H Simon, Seddon, James A, Sharma, Sangeeta, Starke, Jeffrey, Tommasi, Marcela, Triasih, Rina, Furin, Jennifer J
Format: Article
Language:English
Subjects:
Children & youth
Clinical trials
Medical treatment
Multidrug resistant organisms
Pediatrics
Tuberculosis
Viewpoint: Turning the Air Blue
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The past decade has witnessed a transformation in the treatment of rifampicin-resistant/multidrug-resistant (RR/MDR) tuberculosis (TB), with a four-drug, 6-month regimen supported by high-quality evidence now being recommended for most adults. Children (
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.202304-0670VP